AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations
AbbVie (NYSE: ABBV) has announced 20 winners of the inaugural AbbVie Migraine Career Catalyst Award™ contest, supporting career aspirations of people living with migraine. The winners, selected through essay, video, and audio submissions, represent diverse professions including engineers, scientists, teachers, and artists. The initiative addresses the significant impact of migraine on careers, noting that nearly 40 million Americans live with this debilitating neurological disease, resulting in over 113 million work days lost annually in the U.S. Winners will receive support to pursue their professional goals while managing migraine symptoms, demonstrating that career ambitions can extend beyond the disease's impact.
AbbVie (NYSE: ABBV) ha annunciato i 20 vincitori del primo concorso AbbVie Migraine Career Catalyst Award™, a sostegno delle aspirazioni professionali delle persone che vivono con l'emicrania. I vincitori, selezionati attraverso sottomissioni di saggi, video e audio, rappresentano diverse professioni tra cui ingegneri, scienziati, insegnanti e artisti. L'iniziativa affronta l'impatto significativo dell'emicrania sulle carriere, sottolineando che quasi 40 milioni di americani convivono con questa debilitante malattia neurologica, portando a oltre 113 milioni di giorni di lavoro persi annualmente negli Stati Uniti. I vincitori riceveranno supporto per perseguire i loro obiettivi professionali mentre gestiscono i sintomi dell'emicrania, dimostrando che le ambizioni professionali possono andare oltre l'impatto della malattia.
AbbVie (NYSE: ABBV) ha anunciado a los 20 ganadores del primer concurso AbbVie Migraine Career Catalyst Award™, que apoya las aspiraciones profesionales de las personas que viven con migraña. Los ganadores, seleccionados a través de ensayos, videos y presentaciones de audio, representan diversas profesiones, incluidos ingenieros, científicos, maestros y artistas. La iniciativa aborda el impacto significativo de la migraña en las carreras, destacando que casi 40 millones de estadounidenses viven con esta debilitating enfermedad neurológica, lo que resulta en más de 113 millones de días laborales perdidos anualmente en los EE. UU. Los ganadores recibirán apoyo para perseguir sus objetivos profesionales mientras manejan los síntomas de la migraña, demostrando que las ambiciones profesionales pueden extenderse más allá del impacto de la enfermedad.
AbbVie (NYSE: ABBV)는 AbbVie Migraine Career Catalyst Award™ 대회의 첫 번째 수상자 20명을 발표하였으며, 이는 편두통을 앓고 있는 사람들의 직업적 목표를 지원하기 위한 것입니다. 에세이, 비디오 및 오디오 제출을 통해 선정된 수상자들은 엔지니어, 과학자, 교사 및 예술가를 포함한 다양한 직업을 대표합니다. 이 이니셔티브는 편두통이 경력에 미치는 중대한 영향을 다루며, 거의 4000만 명의 미국인이 이 끔찍한 신경학적 질환과 함께 살고 있으며, 이로 인해 미국에서 매년 1억 1300만 일의 근무일이 잃어지고 있다고 설명합니다. 수상자들은 편두통 증상을 관리하면서 자신들의 전문 목표를 추구할 수 있도록 지원을 받게 되며, 이는 직업적 야망이 질병의 영향을 넘어 확장될 수 있음을 보여줍니다.
AbbVie (NYSE: ABBV) a annoncé les 20 lauréats du premier concours AbbVie Migraine Career Catalyst Award™, qui soutient les aspirations professionnelles des personnes vivant avec des migraines. Les lauréats, sélectionnés par le biais de soumissions d'essais, de vidéos et d'audio, représentent diverses professions, notamment des ingénieurs, des scientifiques, des enseignants et des artistes. L'initiative aborde l'impact significatif de la migraine sur les carrières, notant que près de 40 millions d'Américains vivent avec cette maladie neurologique débilitante, entraînant plus de 113 millions de jours de travail perdus chaque année aux États-Unis. Les lauréats recevront un soutien pour poursuivre leurs objectifs professionnels tout en gérant les symptômes de la migraine, démontrant que les ambitions professionnelles peuvent s'étendre au-delà de l'impact de la maladie.
AbbVie (NYSE: ABBV) hat die 20 Gewinner des ersten AbbVie Migraine Career Catalyst Award™ Wettbewerbs bekannt gegeben, der die beruflichen Ambitionen von Menschen mit Migräne unterstützt. Die Gewinner, die durch Essays, Videos und Audio-Beiträge ausgewählt wurden, vertreten verschiedene Berufe, darunter Ingenieure, Wissenschaftler, Lehrer und Künstler. Die Initiative thematisiert die erheblichen Auswirkungen von Migräne auf Karrieren und weist darauf hin, dass nearly 40 Millionen Amerikaner mit dieser schwächenden neurologischen Erkrankung leben, was zu jährlich über 113 Millionen Arbeitsausfällen in den USA führt. Die Gewinner erhalten Unterstützung, um ihre beruflichen Ziele zu verfolgen, während sie die Symptome der Migräne bewältigen, und zeigen damit, dass berufliche Ambitionen über die Auswirkungen der Krankheit hinausgehen können.
- Initiative demonstrates AbbVie's market leadership in migraine treatment with three treatment options
- Program enhances company's brand value and market presence in the neurological disease segment
- None.
- AbbVie Migraine Career Catalyst Award™ contest winners shared inspiring stories and professional goals, showcasing their triumphs over the challenges of living with migraine
- AbbVie, a leader in migraine treatment, is committed to addressing the impact of migraine in the workplace
- Nearly 40 million Americans are living with migraine, a debilitating neurological disease, and are more likely to call in sick due to symptoms associated with migraine.1-2
The 20 winners represent a diverse range of professions, including engineers, scientists, teachers, park service employees, animal shelter workers, artists, and musicians. Beyond their professional roles, these individuals exemplify a rich diversity of life experiences—they are parents, grandparents, students, and caregivers who balance a variety of responsibilities while managing the challenges that migraine symptoms may present. Many have options from the significant advances in treatment in recent years, providing further opportunities to develop in their careers.
"Migraine impacted my life in ways that I hadn't anticipated. I spent most of my career working in state parks, outdoor recreation, and tourism. However, the demands of public service combined with the unpredictability of migraine have made life incredibly challenging," said Melissa from
People living with migraine often face unique challenges in managing their careers1 but these winners exemplify resilience and determination in pursuing their educational and career goals. The AbbVie Migraine Career Catalyst Award™ recognizes their strength and aims to provide the necessary support to help them thrive in their chosen fields, highlighting that their ambitions extend well beyond the impact of migraine.
"Migraine can significantly affect an individual's career trajectory and long-term potential. Despite these challenges, the recipients of the inaugural AbbVie Migraine Career Catalyst Award have shared their remarkable determination to overcome disease-related obstacles as they work toward their professional aspirations," said Jag Dosanjh, senior vice president, AbbVie, and president, neuroscience and eye care. "As the only company with three treatment options that collectively address the entire spectrum of migraine, we have a deep understanding of the challenges that people living with migraine can face in the workplace, and we're proud to support these individuals as they lead lives that transcend obstacles often imposed by the impact of the disease."
Nearly 40 million Americans are living with migraine, a debilitating neurological disease, and are more likely to call in sick due to symptoms associated with migraine.1-2 Over 113 million work days are lost each year in the
Additional 2024 Migraine Career Catalyst Award contest winners on their experience:
- "As someone living with chronic migraine, it never fails to surprise me how often this condition is misunderstood. My migraine has allowed me to experience a greater depth of compassion and empathy for others, and has led to my passion for women's health and social equity," said Anjali from
Washington, D.C. "[This award] will help me pursue law school so that I can dedicate my career towards advocating for healthcare providers and patients." - "As a mom of four with a fifth on the way, there's so much going on that I don't have time for my head to hurt. I work from home, but balancing work, my kids, and migraine is a daily struggle," said Laura from
Mount Juliet, TN. "Migraine doesn't just affect me – it affects my whole family. [This award] means so much to me. I can finally set up a real working space to allow me to work more comfortably and efficiently, reducing the strain that contributes to my migraine in the first place." - "I've been battling migraine for over a decade. I work in video production where bright lights are everywhere – that's a real challenge," said Walter from
Lexington, KY . "I will use the award to get more training and acoustic foam treatment for my workspace to create a quiet work environment. This isn't just about me. This is about showing that with the right support, people with migraine can thrive in their careers."
To see the full list of winners, visit: https://www.migrainecareercatalyst.com/.
About AbbVie in Migraine
Migraine is more than a headache.4 Impacting 1 billion people around the world, migraine is a neurological disease that causes pain and debilitating symptoms.4-8 Our science is helping healthcare providers to care for people across the spectrum of migraine. Through education and partnerships with the migraine community, we strive to help patients, and their families navigate barriers to care, access effective treatments and reduce the impact of migraine on their lives. We are dedicated to the pursuit of MIGRAINE FREEDOM™.
AbbVie is the only company with three prescription treatments designed to meet patient needs across the full spectrum of migraine to help patients living with this debilitating disease. At AbbVie, we are committed to empowering people living with migraine disease. We advance science that enables healthcare providers to care for people impacted across the spectrum of migraine.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
About the AbbVie Migraine Career Catalyst Award™ Contest
AbbVie, a leader in migraine care, recognizes the unique challenges people with migraine face in their professional lives. The AbbVie Migraine Career Catalyst Award™ contest was created to support individuals affected by migraine in pursuing their career aspirations and managing the limitations that migraine can often impose.
Eligible
Information about entering the 2025 contest will be available at www.migrainecareercatalyst.com in June 2025.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
US-NEUM-240098
References:
- Adams AM, Serrano D, et al. Perceived effect of migraine on career and finances: results of the chronic migraine epidemiology and outcomes (CaMEO). ClinicalTrials.gov identifier: NCT01648530. Updated January 29, 2015. Accessed January 19, 2024. clinicaltrials.gov/ct2/show/NCT01648530.
- American Migraine Foundation. What is migraine? January 21, 2021. Accessed January 31, 2024. https://americanmigrainefoundation.org/resource-library/what-is-migraine/
- World Health Organization. Migraine and other headache disorders. March 6, 2024. Accessed October 1, 2024. https://www.who.int/news-room/fact-sheets/detail/headache-disorders
- Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1-211.
- Amiri P, Kazeminasab S, Nejadghaderi SA, Mohammadinasab R, Pourfathi H, Araj-Khodaei M, Sullman MJM, Kolahi AA, Safiri S. Migraine: a review on its history, global epidemiology, risk factors, and comorbidities. Front Neurol. 2022 Feb 23;12:800605. doi: 10.3389/fneur.2021.800605. PMID: 35281991; PMCID: PMC8904749.
- Steiner, T. J., Stovner, L. J., Vos, T., Jensen, R., & Katsarava, Z. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19:17.
- AbbVie. Data on File: ABVRRTI73750.
- Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16:86-92.
View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-awards-20-individuals-living-with-migraine-to-support-career-aspirations-302305019.html
SOURCE AbbVie
FAQ
How many winners did AbbVie (ABBV) select for the 2024 Migraine Career Catalyst Award?
How many work days are lost annually in the US due to migraine according to AbbVie (ABBV)?
How many Americans are living with migraine according to AbbVie's (ABBV) announcement?
What types of professionals were among the AbbVie (ABBV) Migraine Career Catalyst Award winners?
